Capricor Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CAPR Nasdaq 2830 www.capricor.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Capricor Therapeutics, Inc.

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks - Jul 14th, 2025 9:33 am
Capricor Therapeutics Hammered On A Surprise FDA Rejection - Jul 11th, 2025 2:43 pm
Sector Update: Health Care Stocks Retreat Late Afternoon - Jul 11th, 2025 1:39 pm
Sector Update: Health Care Stocks Slide Friday Afternoon - Jul 11th, 2025 11:52 am
Tariff Situation Weighs on Investor Sentiment, Driving Premarket Losses for US Equity Futures - Jul 11th, 2025 6:56 am
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday After Surprise Tariff Hikes - Jul 11th, 2025 6:40 am
Capricor Therapeutics Says FDA Requires Additional Data on Deramiocel; Shares Fall Pre-Bell - Jul 11th, 2025 5:17 am
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy - Jul 11th, 2025 4:30 am
US High Growth Tech Stocks with Promising Potential - Jun 30th, 2025 5:45 am
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls - Jun 26th, 2025 7:49 am
No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital - Jun 25th, 2025 10:15 am
Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright - Jun 25th, 2025 9:05 am
Capricor Therapeutics announces four-year data from HOPE-2 OLE study - Jun 21st, 2025 7:30 am
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy - Jun 20th, 2025 7:25 am
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program - Jun 17th, 2025 7:00 am
Capricor says FDA inspection brought Form 483 with several observations - Jun 12th, 2025 7:35 am
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - Jun 11th, 2025 7:25 am
Exploring 3 High Growth Tech Stocks In The US Market - May 22nd, 2025 11:38 am
Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential - May 21st, 2025 9:22 am
Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results - May 16th, 2025 4:20 am